In the LEAD-6 trial, liraglutide was directly compared with the other available GLP-1 mimetic, exenatide, in people with T2DM inadequately controlled on maximally tolerated doses of metformin, sulfonylurea or both oral agents. Here, GLP1R is linked to type 2 diabetes mellitus.